Beam Therapeutics (BEAM) Change in Acquisitions & Divestments (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $181.3 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $181.3 million, down 16.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.1 million (down 141.28% YoY), and the FY2025 annual result was $5.7 million, changed N/A from the prior year.
• Change in Acquisitions & Divestments climbed to $181.3 million in Q1 2026 per BEAM's latest filing, from -$618.7 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $365.5 million in Q2 2023 and troughed at -$935.0 million in Q4 2023.
• A 5-year average of $81.9 million and a median of $217.1 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments jumped 683.91% in 2022, then tumbled 359.64% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $360.1 million in 2022, then sank by 359.64% to -$935.0 million in 2023, then surged by 41.05% to -$551.1 million in 2024, then retreated by 12.26% to -$618.7 million in 2025, then surged by 129.3% to $181.3 million in 2026.
• Business Quant data shows BEAM's Change in Acquisitions & Divestments at $181.3 million in Q1 2026, -$618.7 million in Q4 2025, and $240.6 million in Q3 2025.